Joint diseases are one of the most common causes of morbidity and disability worldwide.
The main diseases that affect joint cartilage are osteoarthritis and rheumatoid arthritis, which …

Although initially described as an anti-tumor mediator, tumor necrosis factor-alpha (TNF) is
generally considered as the master pro-inflammatory cytokine. It plays a crucial role in the …

Rheumatoid arthritis (RA) is a debilitating autoimmune disease with grave physical,
emotional and socioeconomic consequences. Despite advances in targeted biologic and …

Background Few blinded trials have compared conventional therapy consisting of a
combination of disease-modifying antirheumatic drugs with biologic agents in patients with …

Objective To compare the efficacy and safety of adalimumab plus methotrexate (MTX)
versus MTX monotherapy or adalimumab monotherapy in patients with early, aggressive …

Guidelines and recommendations developed and/or endorsed by the American College of
Rheumatology (ACR) are intended to provide guidance for particular patterns of practice …

Background Methotrexate is considered the preferred disease‐modifying anti‐rheumatic
drug (DMARD) for the treatment of rheumatoid arthritis, but controversy exists on the …

A better understanding of the pathophysiology of rheumatoid arthritis, together with
influential trials aimed at treating early stages of the disease, has altered therapy. This article …

The understanding of the pathogenesis and optimal therapeutics for rheumatoid arthritis
(RA) has advanced remarkably over the last decade. This review highlights these key …

Jo Ledingham1, Nicola Gullick2, Katherine Irving2, Rachel Gorodkin3, Melissa Aris3, Jean
Burke4, Patrick Gordon2, Dimitrios Christidis5, Sarah Galloway6, Eranga Hayes7, Andrew …